Of 107 patients entered into this clinical trial, only 20 patients (19%) were considered to have surgically resectable disease at the time of study entry.
All participants met the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, third revision (DSM-IV-TR) criteria for methamphetamine abuse or dependence and were not seeking treatment at the time of study entry.
RESULTS: Subjects taking aspirin at the time of study entry had a lower numbers of CD133+/34+ cells compared to those not previously exposed (0.01% vs. 0.05% of MNCs, P<0.03).
For each PMRP participant, BMI was accurately defined at the time of study entry (Figure 1).
Only a minority of women entering the vaccine study initiated contraception at the time of study entry.
At the time of study entry no patient used any other drug known to influence glucose metabolism or fat distribution.
Two patients had previously received stereotactic brain irradiation and at the time of study entry had no evidence of recurring CNS disease.
The average age of BAV Genetics Study participants at the time of study entry was 53 years (range 18 to 85), and the majority of subjects are men (54 of 66).
At the time of study entry, 11 of 12 patients in Arm 1 and 10 of 12 patients in Arm 2 had only biochemical relapse with no other evidence of metastatic disease (Table 1).
Patients with known brain metastases were included in the study if they were steroid independent with radiographically stable lesions for at least six weeks after whole brain radiation and no mass effect present radiographically at the time of study entry.
Serology was obtained at the time of study entry.
